AbCellera Biologics Inc. reported $66M of revenue over the trailing twelve months, +101% on the year before. 9 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $66M (to Q2 2026). Net income: −$165M, trailing twelve months to Q2 2026. Free cash flow: −$120M, trailing twelve months to Q2 2026. Operating margin: −789%, trailing twelve months to Q2 2026.

ABCLAbCellera Biologics Inc.

Healthcare

$12.55+178% 1Y

$12.55

$2.7852 weeks$14.83

ABCL as reported

AbCellera Biologics Inc. reported $66M of revenue over the trailing twelve months, +101% on the year before. 9 reported series are charted on this page, each one as filed.

$66M

Revenue, trailing twelve months · to Q2 2026 · +101% against the twelve months before

Net income: −$165M
Net income · −0.61% year on year · trailing twelve months to Q2 2026
Free cash flow: −$120M
Free cash flow · −14% year on year · trailing twelve months to Q2 2026
Operating margin: −789%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for ABCL, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$66M	+101%	Q2 2026
Net income	−$165M	−0.61%	Q2 2026
EPS	−$0.54	−1.8%	Q2 2026
Operating margin	−789%	n/a	Q2 2026
Net margin	−636%	n/a	Q2 2026
ROE	−17%	n/a	Q2 2026
ROA	−12%	n/a	Q2 2026
Free cash flow	−$120M	−14%	Q2 2026
P/E	16.2	n/a	Q4 2022 · 14 quarters behind

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.